Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$2.06
$1.67
$1.31
$2.06
$172.65M0.515 shsN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$14.29
+6.2%
$13.53
$7.30
$16.32
$719.36M-0.1778,003 shs1.14 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.90
-4.9%
$4.50
$2.45
$6.71
$621.61M1.751.40 million shs1.12 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.66
+1.9%
$3.54
$1.77
$10.72
$631.02M1.62.21 million shs1.03 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%0.00%+57.21%+42.03%-10.46%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
0.00%+3.62%+1.89%+0.82%+0.52%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+10.28%+14.19%+83.27%+78.82%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%+2.28%+6.85%+9.12%-47.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.1292 of 5 stars
0.03.00.00.00.01.70.0
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.8533 of 5 stars
3.62.00.04.42.10.80.6
Organogenesis stock logo
ORGO
Organogenesis
4.1497 of 5 stars
3.30.00.04.33.54.20.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.0567 of 5 stars
3.50.00.00.02.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00
N/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.11
Buy$26.2983.94% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5053.06% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.92
Moderate Buy$17.08366.76% Upside

Current Analyst Ratings Breakdown

Latest IPHYF, KALV, ORGO, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $14.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
8/8/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $19.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.00
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $27.00
7/7/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.00
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$21.77M7.93N/AN/A$0.11 per share18.72
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/A$1.92 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.29$0.20 per share24.68$2.09 per share2.34
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M63.04N/AN/A$4.65 per share0.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$183.44M-$3.69N/AN/AN/AN/A-134.07%-82.65%9/4/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%11/5/2025 (Estimated)

Latest IPHYF, KALV, ORGO, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q1 2026
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.91N/AN/AN/A$1.97 millionN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/7/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 million
7/10/2025Q4 2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.83-$3.69-$2.86-$0.99$4.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
2.60
2.60
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
5.35
5.35
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
20.92
20.92

Institutional Ownership

CompanyInstitutional Ownership
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Innate Pharma SA stock logo
IPHYF
Innate Pharma
31.89%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innate Pharma SA stock logo
IPHYF
Innate Pharma
17983.83 million57.10 millionNot Optionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10050.34 million48.18 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330172.41 million164.96 millionOptionable

Recent News About These Companies

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
HC Wainwright Issues Positive Outlook for RLAY Earnings
Equities Analysts Offer Predictions for RLAY Q3 Earnings
Brokers Offer Predictions for RLAY FY2026 Earnings
What is HC Wainwright's Forecast for RLAY FY2026 Earnings?
Relay (RLAY) Q2 Loss Narrows 41%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Innate Pharma stock logo

Innate Pharma OTCMKTS:IPHYF

$2.06 0.00 (0.00%)
As of 08/29/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

KalVista Pharmaceuticals stock logo

KalVista Pharmaceuticals NASDAQ:KALV

$14.29 +0.83 (+6.17%)
Closing price 04:00 PM Eastern
Extended Trading
$14.38 +0.09 (+0.63%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.90 -0.25 (-4.85%)
Closing price 04:00 PM Eastern
Extended Trading
$4.94 +0.04 (+0.92%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.66 +0.07 (+1.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.60 -0.06 (-1.50%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.